Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Everpure, Inc. | Pfizer | |
|---|---|---|
| Moat rating | narrow The FY2026 10-K shows a technology edge that does not dominate its market. On the durable side, the filing states "Our extended advantage stems from three technology differentiators" (direct-to-NAND software, integrated DirectFlash modules and flash-management capabilities), reports over 14,500 customers including "approximately 64% of Fortune 500 companies" and a certified Net Promoter Score of 84, and its income statement shows gross profit of $2,021.2M on $2,830.6M of revenue in FY2024, $2,212.7M on $3,168.2M in FY2025 and $2,578.0M on $3,662.8M in FY2026. On the limiting side, the same filing describes "the intensely competitive data storage market", says many rivals have "substantially greater financial, technical and other resources" and "larger and more mature intellectual property portfolios", and concedes that incumbents keep accounts partly because the customer worries about "actual or perceived costs of switching to a new vendor and technology". IDC's 1Q26 tracker (cited on the array row below) ranks Everpure third, behind Dell and NetApp. A real, technology-based edge held by the number-three vendor is a narrow moat, not a wide one. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip The FY2026 10-K puts the source of advantage in proprietary technology. It names the differentiators as "Direct-to-NAND Software Leadership", "Integrated Hardware–Software DirectFlash Modules" and "Next-Generation Flash Management Capabilities", explains that because its flash-management software "requires less NAND" it avoids SSD over-provisioning, and states that the QLC benefits of FlashArray//C "are only achievable through our DirectFlash integrated hardware and software approach". The company holds "over 3,000 issued patents and patent applications". That technology, not customer lock-in, is what Everpure credits for its hyperscaler design wins. Evergreen's non-disruptive upgrades add a retention layer, but the 10-K's own risk factors show that switching costs mostly favour the incumbents Everpure is displacing, and that rivals hold "larger and more mature intellectual property portfolios" - so the edge is a specific flash-management technique rather than portfolio breadth. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | fast follower IDC's 1Q26 Worldwide Quarterly Enterprise Storage Systems Tracker, as reported by Blocks & Files on 2026-06-16 (the source of the array row below), ranks Everpure third in external enterprise storage behind Dell and NetApp and ahead of Huawei and HPE, noting "Everpure moved into third position helped by subscription model adoption and AI-optimized platforms." By the company's own account it ranks higher on the qualitative axis: its Q2 FY2027 results release of 2026-08-26 (https://s21.q4cdn.com/687136699/files/doc_financials/2027/q2/Q2FY2027-Earnings-Press-Release.pdf) reports it was "Named a Leader in the 2026 Gartner® Magic Quadrant™ for Enterprise Storage Platforms, positioned highest in execution and furthest in vision for the second consecutive year" - the company's own summary of Gartner's opinion. Third by IDC's independent revenue ranking, with the higher Gartner placement resting on the company's own account, reads as a close follower to Dell and NetApp rather than a shared lead. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate It can pass costs through but not escape them. The 10-K's income statement reports gross profit of $2,021.2M, $2,212.7M and $2,578.0M on revenue of $2,830.6M, $3,168.2M and $3,662.8M for FY2024-FY2026. When component costs rose, the 10-K says "we raised our prices during the first quarter of fiscal year 2027", and the Q2 FY2027 results release (https://s21.q4cdn.com/687136699/files/doc_financials/2027/q2/Q2FY2027-Earnings-Press-Release.pdf) quotes the CFO: "Demand remains strong across our solutions portfolio despite historic industry price increases in the first half of FY'27." Those were industry-wide increases, though, and margin still slipped: GAAP gross margin was 68.4% in Q2 FY2027, against gross profit of $604.3M on $861.0M of revenue a year earlier. The 10-K adds that "ongoing component cost volatility has placed, and may continue to place, downward pressure on our gross margins" and that some competitors offer storage "at significant discounts or even for free". | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Everpure (renamed from Pure Storage) sells all-flash storage built on one design choice it has pursued since FlashArray, which the FY2026 10-K calls "the industry's first all-flash array": its own software manages raw NAND directly instead of going through commodity SSDs. The filing names three differentiators built on that choice and says the Purity operating environment is shared across FlashArray, FlashBlade and the Everpure Cloud services. The design is what let Everpure put dense QLC flash into enterprise arrays, and what won "the industry-first Flash design win with a major hyperscaler"; the company's Q2 FY2027 results release (2026-08-26) adds a second top-five hyperscaler win on the same DirectFlash architecture. Around the hardware sits Evergreen, which replaces controllers and flash modules in place so arrays do not need wholesale replacement, and a customer base the 10-K puts at over 14,500, including about 64% of the Fortune 500, with a certified NPS of 84. The 10-K's income statement reports gross profit of $2,021.2M on $2,830.6M of revenue in FY2024, $2,212.7M on $3,168.2M in FY2025 and $2,578.0M on $3,662.8M in FY2026. The limits are just as explicit. IDC's 1Q26 tracker ranks Everpure third in external enterprise storage, behind Dell and NetApp. The 10-K concedes that rivals have larger and more mature IP portfolios, that most prospects already run a competitor's storage and incumbents keep them partly through switching costs, and that public cloud providers "known for developing storage systems internally" reduce demand for systems like Everpure's. Component costs are the other exposure: the filing says the cost of components "increased significantly" in fiscal 2026, and that price increases in the first quarter of fiscal 2027 were meant "to help offset these rising expenses" while volatility keeps pressure on margins. A real, technology-based edge, held by a vendor that is third by revenue: narrow, not wide. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Everpure sits between the flash-memory supply and enterprise and hyperscale data centres. Upstream, the FY2026 10-K names "the cost of components, including flash and DRAM" as a gross-margin driver, says it must ensure "a sufficient supply of flash to support our hyperscaler customer", develops DirectFlash "In close collaboration with key QLC flash partners", and relies on contract manufacturers to build its products. Downstream it sells through a direct sales force and channel partners to enterprises, managed service providers and hyperscalers, and lists Microsoft Azure, AWS, Google, IBM, Cisco and NVIDIA among its technology partners; large public cloud providers are at once partners and, through internally developed storage, substitutes. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |